Xuexia Shan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xuexia Shan has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Hui-Xiong Xu
Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, China
2 shared publications - Li-Ping Sun
Department of Medical Ultrasound, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications - Shaoyue Li
Department of Medical Ultrasound and Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, P. R. China
2 shared publications Shuo Liu
Department of Medical Ultrasound Shanghai Municipal Hospital of Traditional Chinese Medicine Shanghai University of Traditional Chinese Medicine Shanghai P. R. China
2 shared publicationsWeiwei Ren
Department of Medical Ultrasound Center of Minimally Invasive Treatment for Tumor Shanghai Tenth People's Hospital School of Medicine Tongji University Shanghai P. R. China
2 shared publications- Wenwen Yue
Center of Minimally Invasive Treatment for Tumor, Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai, China
2 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Wiley in Advanced Science
Targeting Macrophage‐Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation
Microwave ablation (MWA) is an effective locoregional therapy for solid tumors, but recurrence caused by minimal residual disease remains a clinical challenge. Although immunotherapy offers a strategy to prevent recurrence, the role of tumor‐draining lymph nodes (TDLNs) in post‐ablation immune regulation remains underexplored. Here, single‐cell RNA sequencing (scRNA‐seq) reveals pronounced macrophage remodeling in TDLNs following incomplete MWA (iMWA), characterized by an increased representation of immunosuppressive Folr2 + and Apoe + macrophage subsets. These populations exhibit broad colony‐stimulating factor 1 receptor ( Csf1r ) expression, accompanied by enhanced CSF signaling and macrophage‐centered intercellular communication, implicating CSF1R‐associated macrophage remodeling in post‐ablation immunosuppression. Accordingly, an albumin‐based lipoprotein nanosystem co‐encapsulating paclitaxel (PTX) and the CSF1R inhibitor BLZ945 (PTX/BLZ945@Alb‐lip) was developed. Across multiple tumor models, PTX/BLZ945@Alb‐lip enhances immunomodulator delivery to both TDLNs and tumors, remodels the macrophage‐mediated immunosuppressive microenvironment, and suppresses residual tumor growth after iMWA. Moreover, treatment promotes durable antitumor immune memory and protects cured mice against tumor rechallenge. These findings identify TDLNs as an important therapeutic site in post‐ablation immunotherapy and provide a potential strategy to prevent tumor recurrence following ablation.
- 28 September 2026
- Published by Wiley in Advanced Science
Open AccessTargeting Macrophage‐Mediated Lymphatic Immunosuppression to Prevent Tumor Recurrence After Microwave Ablation
Microwave ablation (MWA) is an effective locoregional therapy for solid tumors, but recurrence caused by minimal residual disease remains a clinical challenge. Although immunotherapy offers a strategy to prevent recurrence, the role of tumor‐draining lymph nodes (TDLNs) in post‐ablation immune regulation remains underexplored. Here, single‐cell RNA sequencing (scRNA‐seq) reveals pronounced macrophage remodeling in TDLNs following incomplete MWA (iMWA), characterized by an increased representation of immunosuppressive Folr2 + and Apoe + macrophage subsets. These populations exhibit broad colony‐stimulating factor 1 receptor ( Csf1r ) expression, accompanied by enhanced CSF signaling and macrophage‐centered intercellular communication, implicating CSF1R‐associated macrophage remodeling in post‐ablation immunosuppression. Accordingly, an albumin‐based lipoprotein nanosystem co‐encapsulating paclitaxel (PTX) and the CSF1R inhibitor BLZ945 (PTX/BLZ945@Alb‐lip) was developed. Across multiple tumor models, PTX/BLZ945@Alb‐lip enhances immunomodulator delivery to both TDLNs and tumors, remodels the macrophage‐mediated immunosuppressive microenvironment, and suppresses residual tumor growth after iMWA. Moreover, treatment promotes durable antitumor immune memory and protects cured mice against tumor rechallenge. These findings identify TDLNs as an important therapeutic site in post‐ablation immunotherapy and provide a potential strategy to prevent tumor recurrence following ablation.
- Open Access
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadw2937
Targeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with pronounced resistance to conventional therapies. Irreversible electroporation (IRE) is a promising therapy for PDAC; however, its clinical efficacy is limited by a high recurrence rate. Here, using a preclinical PDAC model, we characterized the tumor immune microenvironment following insufficient IRE (iIRE) through single-cell RNA sequencing. We found that iIRE induces a CCR2 + tumor-associated macrophage (CCR2 + TAM)–mediated immunosuppressive microenvironment in residual tumors. Consequently, we developed a macrophage-based proteolipid vesicle (mPLV) coencapsulating the CCR2 antagonist PF-4136309 (PF) and gemcitabine (GEM), named PF/GEM@mPLV. Our findings suggest that PF/GEM@mPLV achieves high drug accumulation within tumors through iIRE-induced inflammation. Reduction of CCR2 + TAMs enhances antitumor immunity and improves chemotherapeutic response. PF/GEM@mPLV markedly inhibits tumor recurrence following iIRE, diminishes hepatic metastases, and prolongs survival in preclinical PDAC models. These findings uncover the role of CCR2 + TAMs in iIRE-induced immunosuppression, offering a promising strategy to enhance the clinical potential of IRE in PDAC.
- 25 July 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 11 (30) , eadw2937
Open AccessTargeting tumor-associated CCR2 + macrophages to inhibit pancreatic cancer recurrence following irreversible electroporation
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with pronounced resistance to conventional therapies. Irreversible electroporation (IRE) is a promising therapy for PDAC; however, its clinical efficacy is limited by a high recurrence rate. Here, using a preclinical PDAC model, we characterized the tumor immune microenvironment following insufficient IRE (iIRE) through single-cell RNA sequencing. We found that iIRE induces a CCR2 + tumor-associated macrophage (CCR2 + TAM)–mediated immunosuppressive microenvironment in residual tumors. Consequently, we developed a macrophage-based proteolipid vesicle (mPLV) coencapsulating the CCR2 antagonist PF-4136309 (PF) and gemcitabine (GEM), named PF/GEM@mPLV. Our findings suggest that PF/GEM@mPLV achieves high drug accumulation within tumors through iIRE-induced inflammation. Reduction of CCR2 + TAMs enhances antitumor immunity and improves chemotherapeutic response. PF/GEM@mPLV markedly inhibits tumor recurrence following iIRE, diminishes hepatic metastases, and prolongs survival in preclinical PDAC models. These findings uncover the role of CCR2 + TAMs in iIRE-induced immunosuppression, offering a promising strategy to enhance the clinical potential of IRE in PDAC.